Novartis AG (NVS)
132.57
+0.21
(+0.16%)
USD |
NYSE |
Dec 12, 16:00
132.56
-0.01
(-0.01%)
Pre-Market: 20:00
Novartis Research and Development Expense (Quarterly): 2.857B for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Amgen, Inc. | 1.90B |
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Avidity Biosciences, Inc. | 154.95M |
| Monte Rosa Therapeutics, Inc. | 34.58M |